About: Combination of sphingosine-1-phosphate receptor 1 (S1PR1) agonist and antiviral drug: a potential therapy against pathogenic influenza virus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Combination of sphingosine-1-phosphate receptor 1 (S1PR1) agonist and antiviral drug: a potential therapy against pathogenic influenza virus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Combination of sphingosine-1-phosphate receptor 1 (S1PR1) agonist and antiviral drug: a potential therapy against pathogenic influenza virus
Creator	Shi, Yi Jiang, Hao Su, Xin Zhao, Jiangnan Shen, Simen Zhu, Meiying
Source	PMC
abstract	The pandemic 2009 influenza A H1N1 virus is associated with significant mortality. Targeting S1PR1, which is known to modulate the immune response, provides protection against pathogenic influenza virus. The functional role and molecular mechanism of S1PR1 were analysed by generating inducible endothelial cell-specific S1PR1 knockout mice and assessing the therapeutic efficacy of the selective S1PR1 agonist CYM5442 against acute lung injury (ALI) induced by the 2009 influenza A H1N1 virus. Immune-mediated pulmonary injury is aggravated by the absence of endothelial S1PR1 and alleviated by treatment with CYM-5442, suggesting a protective function of S1PR1 signaling during H1N1 infection. S1PR1 signaling does not affect viral clearance in mice infected with influenza. Mechanistically, the MAPK and NF-kB signaling pathways are involved in the ALI mediated by S1PR1 in infected mice. Combined administration of the S1PR1 agonist CYM-5442 and the antiviral drug oseltamivir provides maximum protection from ALI. Our current study provides insight into the molecular mechanism of S1PR1 mediating the ALI induced by H1N1 infection and indicates that the combination of S1PR1 agonist with antiviral drug could potentially be used as a therapeutic remedy for future H1N1 virus pandemics.
has issue date	2019-03-27(xsd:dateTime)
bibo:doi	10.1038/s41598-019-41760-7
bibo:pmid	30918324
has license	cc-by
sha1sum (hex)	e62e5dc47b22bec9e51db6d489c0a1aade95d7cf
schema:url	https://doi.org/10.1038/s41598-019-41760-7
resource representing a document's title	Combination of sphingosine-1-phosphate receptor 1 (S1PR1) agonist and antiviral drug: a potential therapy against pathogenic influenza virus
has PubMed Central identifier	PMC6437142
has PubMed identifier	30918324
schema:publication	Sci Rep
resource representing a document's body	covid:e62e5dc47b22bec9e51db6d489c0a1aade95d7cf#body_text
is schema:about of	named entity 'functional' named entity 'influenza A' named entity 'involved' named entity 'modulate' named entity 'S1PR1' named entity 'H1N1' named entity 'efficacy' named entity 'S1PR1' named entity 'THERAPEUTIC' named entity 'DOES NOT' named entity 'PULMONARY INJURY' named entity 'S1PR1' named entity 'AGGRAVATED BY' named entity 'mice' named entity 'study' named entity 'pandemics' named entity 'MAPK' named entity 'pulmonary injury' named entity 'mechanism' named entity 'virus' named entity 'ALI' named entity 'ALI' named entity 'generating' named entity 'infected' named entity 'NF-kB' named entity 'S1PR1' named entity 'influenza' named entity 'antiviral drug' named entity 'mice' named entity 'mice' named entity 'signaling pathways' named entity 'S1PR1' named entity 'molecular mechanism' named entity 'molecular mechanism' named entity 'influenza' named entity 'agonist' named entity 'CCL2' named entity 'ERK1/2' named entity 'conjugated' named entity 'infection' named entity 'phosphorylated' named entity 'infection' named entity 'oseltamivir' named entity 'infection' named entity 'oseltamivir' named entity 'β-actin' named entity 'antibodies' named entity 'immunofluorescence' named entity 'survival rates' named entity 'BALF' named entity 'hyaline' named entity 'haemorrhaging' named entity 'heterodimers' named entity 'bradycardia' named entity 'inflammatory cell' named entity 'Biosafety Level 2' named entity 'SYBR Green' named entity 'influenza A virus' named entity 'real-time RT-PCR' named entity 'IFN-γ' named entity 'receptor agonists' named entity 'antibodies' named entity 'NF-κB' named entity 'protease inhibitors' named entity 'gene' named entity 'S1PR1' named entity 'BALF' named entity 'MAPK' named entity 'Histopathology' named entity 'signaling molecules' named entity 'ERK1/2' named entity 'Jinling' named entity 'inflammatory response' named entity 'BALF' named entity 'S1PR1' named entity 'S1PR1'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software